Retrospective analysis evaluates efficacy and tolerability of pembrolizumab with chemotherapy in cervical cancer, suggesting implications for treatment strategies.
Metastatic and recurrent cervical cancer remains associated with poor prognosis. The KEYNOTE-826 trial established a new standard of care combining the checkpoint inhibitor pembrolizumab with platinum-based chemotherapy, with or without bevacizumab. We evaluated the efficacy and tolerability of this combination in a real-world setting.
No takes yet. Share an insight, caveat, or question.
Ruscito et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: